Stockscreener 앱 받기
1.46
4.29%
0.06
전일 마감가:
$1.40
열려 있는:
$1.42
하루 거래량:
465.91K
Relative Volume:
0.63
시가총액:
$29.59M
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
-9.32%
1개월 성능:
-3.31%
6개월 성능:
-82.43%
1년 성능:
-93.33%
1일 변동 폭
$0.00
$0.00
1주일 범위
$1.39
$1.63
52주 변동 폭
$0.9601
$42.61
SRX Global Inc Stock (SRXH) Company Profile
Compare SRXH vs JBS, KHC, GIS, SJM, MKC.V
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRXH
SRX Global Inc
|
1.46 | 29.59M | 0 | 0 | 0 | 0.00 |
JBS
Jbs Nv
|
12.98 | 42.70B | 88.25B | 1.91B | -681.64M | 1.6761 |
KHC
Kraft Heinz Co
|
22.27 | 26.41B | 24.99B | -5.76B | 3.95B | -4.863 |
GIS
General Mills Inc
|
32.29 | 17.27B | 18.42B | -85.30M | 1.63B | -0.1894 |
SJM
J M Smucker Co
|
119.83 | 12.80B | 9.05B | -138.70M | 1.16B | -1.307 |
MKC.V
McCormick & Company, Incorporated Voting CS
|
46.73 | 12.57B | 0 | 0 | 0 | 0.00 |
SRX Global Inc 주식(SRXH)의 최신 뉴스
SRX Global Inc. (SRXH) stock price, news, quote and history - Yahoo Finance Singapore
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies - GlobeNewswire Inc.
Three patients got a higher CER-1236 dose; no dose-limiting toxicities were observed. Results are preliminary. - Stock Titan
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into - GlobeNewswire
SRX Global Inc. entered into a Stock Purchase Agreement to acquire CERo Therapeutics, Inc. from CERo Therapeutics Holdings, Inc. for 10.8 million. - www.marketscreener.com
CERo Therapeutics to Sell Operating Subsidiary to SRX Global for $1M in Stock Plus Debt Relief - TradingView
SRX Global Allocates $1.5M to Launch Actively Managed ETFs via EMJX Platform with Kupa Inc. - Kalkine Media
SRX Global Inc. Announces Plans To Launch Family Of AI-Powered ETFs Through Its EMJX Platform - www.marketscreener.com
SRX Global Commits $1.5 Million to Launch Family of - GlobeNewswire
SRX Global commits $1.5M to launch AI-powered ETFs on EMJX, plans dividend of ETF holdings - TradingView
A planned shareholder dividend accompanies SRX Global’s (SRXH) commitment to launch active ETFs. - Stock Titan
SRX Global Company Profile & Introduction - Moomoo
SRX Global Inc. (SRXH) stock price, news, quote and history - Yahoo Finance UK
SRX Global Inc. (SRXH) Stock Price, News, Quote & History - Yahoo! Finance Canada
SRX Global Inc. (SRXH) stock price, news, quote and history - Yahoo Finance Australia
SRX Global Inc. acquired an unknown minority stake in Onconetix, Inc.. - marketscreener.com
SRX Global Makes Investment in Onconetix - Yahoo Finance
A robot's eyes hold cameras. SRX Global invested in Onconetix, which has an agreement to acquire Realbotix. - Stock Titan
SRX Global Provides Shareholders with Update on Liquidation - GlobeNewswire
SRX Global Provides Shareholders with Update on Liquidation - GlobeNewswire
SRX Global Provides Shareholders With Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO) - Moomoo
A robot's eyes hold cameras. SRX Global invested in Onconetix, which has an agreement to acquire Realbotix. - Stock Titan
SRX Global CEO Kent Cunningham and President of EMJX - GlobeNewswire
A free Webull account is needed to watch SRX Global's Sept. 30 webinar live. - Stock Titan
SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar - Yahoo Finance
SRX Global (SRXH) gets holder consent to buy back up to 10M shares - Stock Titan
SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company - Yahoo Finance
A fentanyl vaccine produced an immune response in humans. ARMR is testing doses. - Stock Titan
SRX Global (SRXH) lines up $11.7M for CERo, backed by its cell therapy assets - Stock Titan
SRX Global Inc (SRXH) (Q3 2026) Earnings Call Highlights: Strategic EMJX Acquisition and Record ... - Yahoo Finance
SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results - GlobeNewswire
SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET - Yahoo Finance
SRX Global (SRXH) Acquires Stake in Vistagen Therapeutics - Yahoo Finance
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - GlobeNewswire
SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger - GlobeNewswire
SRX Global Regains Full Compliance with NYSE American Listing Standards - Yahoo Finance
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026 - GlobeNewswire
SRX Global Board of Directors Authorizes Stock Repurchase - GlobeNewswire
SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding - Yahoo Finance
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1) - Yahoo Finance
SRX Global Reports Preliminary June 30, 2026 Balance Sheet Update, About $40 Million in Cash and No Debt Following EMJX Acquisition and Reverse Split | SRXH Stock News - Quiver Quantitative
SRX Global Declares One-Time Cash Dividend - GlobeNewswire
SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines - GlobeNewswire
SRX Global Announces Share Consolidation - Yahoo Finance
SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences - GlobeNewswire
SRX Global Inc (SRXH) 재무 분석
SRX Global Inc (SRXH)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.19%
3.81%
자본화:
|
볼륨(24시간):